Background. Liver allografts are accepted across major histocompatibility complex (MIlC) barriers in mice and induce donor-specific tolerance without requirement for immunosuppressive therapy. There is evidence that passenger leukocytes may play a key role in tolerance induction. FIt-3 ligand (FL) is are-cently cloned hematopoietic cytokine that strikingly augments functional dendritic cells (DCs) within lymphoid and nonlymphoid tissue.
Methods. The expression of costimulatory molecules and MIIC class II antigen on DCs isolated from livers of FL-treated BIO (H2 b ) mice (10 Ilglday; 10 days) was examined by flow cytometric analysis, and their allo stimulatory activity assessed in primary mixed leuko cyte cultures. BI0 livers from FL-treated donors were transplanted orthotopically into naive C3H (H2k) recipients. Donor cells (MIle class 11+) in recipient spleens were identified by immunohistochemistry. Antidonor cytotoxic T lymphocyte activity, and both natural killer and lymphokine-activated killer cell activities of graft nonparenchymal cells and host splenocytes were determined using isotope release assays. Apoptotic activity within liver grafts was determined by terminal deoxynucleotidyltransferase-mediated Results. DCs isolated from livers of FL-treated donor mice exhibited increased cell surface expression of CD40, CD80, CD86, and lAb, and augmented T cell allostimulatory activity compared with controls. Within 24 hr of organ transplantation, the numbers of donor IA b + cells within recipient spleens was augmented substantially compared with normal liver recipients. Livers from FL-treated donors were rejected acutely (median survival time, 5 days), whereas control BI0 liver allografts survived > 100 days. Nonparenchymal cells from rejecting grafts 4 days after transplantation exhibited increased antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities compared with cells from spontaneously accepted grafts. This augmented cytotoxic reactivity was associated with histologic evidence of injury to bile duct epithelium and vascular endothelium that was not readily evident in controls.
Conclusion.. Thus, although normal livers provide allostimulatory signals sufficient to elicit an antidonor immune response, regulatory mechanisms that may include apoptosis of graft-infiltrating T cells, and that are overcome by augmenting the number of functional donor DCs, may account for inherent liver tolerogenicity.
In most mouse and certain rat strain combinations, liver allografts are accepted across major histocompatibility complex (MHC*) barriers, and induce donor-specific tolerance, without the need for immunosuppressive therapy (1) . Why this occurs frequently with the liver (and only exceptionally for mouse heart or kidney) is poorly understood. Mechanisms suggested to account for liver tolerogenicity (reviewed in 2 and 3) include low constitutive MHC antigen expression by hepatocytes, immunoregulatory effects of soluble hepatocyte products or donor MHC class I antigens, "insufficiency" of T helper-l cell cytokines (4), "tolerogenic" donor-derived antigen-presenting cells (APCs) (5), and contrastingly, "superinduction" of T cell responses (resulting in proliferative clonal exhaustion and deletion; 6). There is evidence that "passenger" leukocytes may play a key role in determining the outcome of allogeneic liver transplantation. Compared with the heart or kidney, the liver is comparatively rich in interstitial leukocytes, including APCs, and in particular, dendritic cells (DCs) (7, 8) . Persistence of multiline age donor-derived leukocytes, including DC progenitors, in recipient tissues is associated with liver transplant tolerance (1, 5, (9) (10) (11) (12) . Moreover, in spontaneous liver acceptance models, depletion of passenger leukocytes from the donor organ results in allograft rejection (13) . We have suggested recently (14) that apoptosis of alloactivated T cells infiltrating liver portal areas (that are rich in DCs; 8) may be a mechanism underlying liver transphmt tolerance.
DCs represent only a small proportion of the interstitial leukocytes within normal tissue (15) . Unlike DCs resident within lymphoid tissue such as spleen, freshly isolated MHC
• Abbreviations: APC, antigen-presenting cell; BM, bone marrow; CTL, cytotoxic T lymphocyte; DC, dendritic cell; FL, FIt-3 ligand; IL, interleukin; LAK, lymphokine-activated killer; MHC, major histocompatibility complex; NPC, non parenchymal cell; NK, natural killer; PBS, phosphate-buffered saline; RT, room temperature; TdT, terminal deoxynucieotidyltransferase; TUNEL, TdT-mediated dUTP-biotin nick end labeling.
class n+ DCs from nonlymphoid organs are poor allostimulators (16, 17) . This is consistent with the apparent lack of invariant chain (18) , and low or absent costimulatory molecule expression (19) that suggests these nonlymphoid tissue DCs may have tolerogenic properties. Indeed, DC progenitors propagated from normal liver and administered systemically can prolong allograft survival in mice (20) . Other evidence points to potential tolerogenicity of DCs (21) (22) (23) (24) . These and other findings (2, 5) indicate that liver tolerogenicity may reflect quantitative and/or qualitative deficiencies in the capacity of the donor APC population, in particular DCs, to elicit an effective immune response.
FIt-3 ligand (FL) is a recently cloned hematopoietic growth factor (25) , the cognate ligand of FIt-3, a receptor-type III tyrosine kinase (26) that is expressed on CD34 + stem cells. FL administration is highly effective in mobilizing stem and progenitor cells in vivo (27) and results in their accumulation in tissues. Unlike granulocyte-macrophage colony-stimulating factor, the essential myeloid DC growth factor in vitro, FL dramatically and selectively increases the number of nmctional DCs in mouse lymphoid and nonlymphoid tissues (28) . Recently, we reported that increasing the number of liver passenger leukocytes (in particular, the proportion of potential allostimulatory DCs) by donor pretreatment with FL prevented the induction of liver transplant tolerance (29) . We now show that augmentation of functional donor DCs in this passenger leukocyte population is associated with large increases in the number of donor-derived APCs within recipient lymphoid tissue, and with augmentation of antidonor cytotoxic T lymphocyte (CTL), natural killer (NK), and lymphokine-activated killer (LAK) cell activities of graft-infiltrating cells. Transplantation of livers from FL-treated donors was also associated with an altered pattern of in situ apoptotic activity. Thus, rather than inducing high dose unresponsiveness, a large increase in delivery/presentation of donor alloantigen can overcome tolerance-inducing mechanisms, and promote the expression of immune effector mech-""oG , ... 
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Vol. 65, No. 12 anisms consistent with bile duct and vascular cell injury leading to acute liver rejection. Liver nonparenchymal cell (NPC) isolation and DC culture. Livers from FL-treated or control mice, or liver allografts were pooled (three to five animals per experiment). NPCs were isolated by collagenase digestion, followed by Percoll centrifugation (30) . The NPCs comprised predominantly CD45+ leukocytes (at least 95% in both control and FL-treated animals). Metrizamide-purified DC preparations were obtained by overnight (18 hr) culture of liver Npr i, followed by centrifugation of the nonadherent cells over metrizam ;e (14.5% w/v, Sigma Chemical, St. Louis, MO), as described (8) .
MATERIALS AND METHODS
Animals
Immunophenotypic analysis of cell suspensions. Immunofluorescence staining of cell-surface antigens for flow cytometric analysis, including double-labeling to identify the origin of the cells, was performed as described previously (30) anti~ens were detected using hybridoma N418 (31) and NLDC-145 (32) monoclonal antibody supernatants, respectively, that were provided by Dr. R.M. Steinman (Rockefeller University, New York, NY). Appropriate rat, hamster, or mouse Ig isotype controls were included in each experiment. Flow cytometric analysis was performed using a EPICS Elite flow cytometer (Coulter Corp., Hialeah, FL). Five thouland events were acquired for each sample. Cytocentrifuge preparations were stained with Giemsa or by immunocytochemistry (30, 33) . Allostimulatory activity. One-way mixed leukocyte reaction cultures were established in 96-well round-bottom microculture plates. Graded doses of r-irradiated (20 Gy; x-ray source) syngeneic or allogeneic (BID) stimulator cells were added to 2xlO" nylon wooleluted C3H spleen cells (8) Organ transplantation. Orthotopic liver transplantation was performed from either FL-treated or control BID donors to C3H recipients, as described (34) . No immunosuppressive therapy was given. Rejection was confirmed histologically.
Immunohistology. Staining for donor MHC class II+ (IA b +) cells in cryostat sections of recipient spleens was performed as described previously in detail (30) .
CTL assays. Freshly isolated liver NPCs or spleen cells from either allograft recipients or control C3H mice were used as effectors at various effector-to-target cell ratios. The EL4 (H2 b ) lymphoma cell line (TIB39; American Type Culture Collection [ATCC), Rockville, MD) was used as a source of donor-specific target cells (ATCC) in 4-hr 51Cr release assays, as described (14) . The percent specific cytotoxicity was calculated using the following formula: % cytotoxic-
Results are expressed as means :!:lSD of percent specific 51Cr release in triplicate cultures.
Quantitation of NK and LAX cell activities. Lysis of YAC-1 tumor cells detected by 4-hr 51Cr release assay was used as an indicator of NK cell activity, whereas LAK cell activity and cytotoxicity towards third-party targets was determined by lysis of NK-resistant 51Cr_ labeled P-8l5 (H2 d ) tumor cells (ATCC) (35) . The tumor cell lines were grown in RPMI-1640 complete medium (Life Technologies, Gaithersburg, MD) and were subcultured two to three times per week.
In --" ' ------------ , and the reaction developed with 3-amino-5-ethycarbizol. Slides counterstained with Harris' hematoxylin and mounted with tal mount (Biomeda Corp., Foster City, CAl. tatistical analyses. Statistical analyses were performed using ent's t test or the Mann-Whitney U test, as appropriate.
RESULTS
'Markedly increased numbers of allostimulatory DCs can be
ted from liver NPCs of FL-treated mice. As reported 'ously (29) , there was a large increase in the absolute ber of liver leukocytes (NPCs) in FL-treated animals, uding a substantia130-50-fold increase, compared to conls, in cells bearing the myeloid markers, Gr-1 and MAC-1 , llb). There was also a large increase both in the relative absolute numbers of cells that were positive for the -restricted antigens, CDllc or DEC 205 (data not shown). i;:vestigate the liver DCs, highly purified preparations " "'" obtained after overnight (18 hr) culture of NPCs, and ;,:elntrifugation of nonadherent cells over metrizamide. Com-
Ii " to control animals, from which only approximately , ", 10" DCs could be harvested per liver, about 6x 10 6 DCs .' ,," d be recovered from livers of 10-day FL-treated mice. The ' . displayed morphologic and surface phenotypic features acteristic of DCs (Fig. 1) , and were DEC 205+, F4J80-, Ohi, CD80+, CD86 h \ and MHC class II (IAb)hi. The extent . lymphocyte contamination was very low. Significantly, an j 'tional3x10 6 DCs/liver could be harvested after a second of culture of cells from FL-treated mice in the absence of ulocyte-macrophage colony-stimulating factor. Adelia! flow cytometric and immunocytochemical analyses in-" , ted that overnight-cultured DCs from NPCs of both con-.,~.','". ,,' I and FL-treated mouse livers expressed similar levels of ."
C class II (lAb) (Fig. 2) , but that higher levels of CD40, '. 80 and CD86 were expressed on DCs from FL-treated !jmce (Fig. 3) . This suggested that the DC population present 'Ia FL-t n~ated livers was in a later stage of phenotypic mat-. tion than that in controls. Consistent with their higher levels of expression of costimulatory molecules, DCs from FL-treated livers exhibited significantly increased allostimulatory activity for naive T cells compared to DCs from controls (Fig. 4) .
FL treatment of organ donors results in acute liver allograft rejection.
In the B10 to C3H strain combination, orthotopic liver allografts are accepted spontaneously in nonimmunosuppressed recipients. Treatment of liver donors with FL for 10 days, however, resulted in the acute rejection of livers in all allograft recipients (median survival time, 5 days) ( Table  1) . Liver allograft rejection was confirmed histologically.
Increased donor MHC class IJ+ cells are observed in spleens of recipients of livers from FL-treated donors.
Immunohistochemical staining of spleens from recipients of hepatic allografts 24 hr after transplant revealed substantial increases in donor MHC class 11+ (IA b +) cells in those mice given livers from FL-treated donors compared with controls (data not shown).
FL pretreatment of liver donors augments CTL, NK, and LAK cell activities of graft-infiltrating cells. Similar numbers of graft-infiltrating cells with comparable immunophenotypic
characteristics were isolated from the transplanted livers of control and FL-treated donors. By day 4 after transplant, >80% of these cells expressed recipient MHC class I phenotype (H2K k ); of these, approximately 25% were CD4 + and 30% CD8 +. It has been shown previously that freshly isolated graft-infiltrating cells of normal liver allografts exhibit ex vivo antidonor CTL activity for a short period after transplantation (14) . This activity gradually subsides to normal levels as the grafts are accepted permanently. To test the antidonor responses of graft-infiltrating cells within livers from FL-treated donors, CTL, NK, and LAK cell activities were evaluated 4 days after transplantation. As shown in Figure 5 , there were increases in all three activities when compared with those exhibited by cells isolated from control liver allografts. Corresponding activities of host spleen cells were also evaluated. There was increased antidonor CTL activity of spleen cells from mice given livers from FL-treated donors compared with the modest activity of control liver recipients' splenocytes. However, no alteration in the low NK and LAK cell activities of corresponding host spleen cells was observed.
Increased bile duct and hepatocellular injury in liver grafts from FL-treated donors. Liver grafts harvested from experimental and control animals were examined histologically 4 days after transplantation. As reported previously (1), there was little evidence of damage to bile duct epithelium, hepatocytes or vascular endothelial cells in control liver grafts, despite a prominent (mainly periportaVperivascular) inflammatory cell infiltrate. In contrast, liver grafts from FLtreated donors, examined at the same time after transplant, exhibited an extensive, generalized mononuclear cell intil- trate, with clear evidence of bile duct damage, and vascular endothelial cell injury (Fig. 6, A-D) . These findings were consistent with acute liver rejection (median survival time, 5 days) in recipients of grafts from FL-treated donors.
Apoptotic activity of liver parenchymal cells is enhanced and that of inflammatory cells decreased in liver grafts from FL-treated donors.
It has been shown recently that spontaneous liver allograft acceptance in mice is associated with a relatively high incidence of apoptotic cells within the periportal inflammatory cell infiltrate, that may be linked to deletion of donor-reactive CTL (14) . In view of these observations, we compared apoptotic activity in allografts from FL-treated donors with those from control liver grafts, using the TUNEL assay for in situ DNA fragmentation. As shown in Figure 6 (E-H), there was a striking increase in the number of large apoptotic cells (presumed hepatocytes) throughout the parenchyma of livers from FL-treated donor compared with control liver grafts. The differential increase in apoptotic death of parenchymal cells was associated with a reduced incidence of TUNEL-positive inflammatory cells. This was consistent with the elevated levels of antidonor CTL activity of freshly isolated graft-infiltrating cells, and with increased numbers of inflammatory cells throughout the liver lobules compared with controls.
DISCUSSION
The present study describes a model of mouse liver allograft rejection that is dependent on donor pretreatment with the potent hematopoietic growth factor FL. Rejection is associated with: (i) dramatic increases in the numbers of potential allostimulatory DCs that can be recovered from the donor organ using conventional DC isolation procedures; (ii) substantial increases in donor MHC class IP cells within recipient lymphoid tissue 24 hr after transplant; (iii) potentiation of antidonor CTL, NK, and LAK cell activities within the graft; and (iv) reduced apoptotic activity of graft-infiltrating cells. In virtually all H2-incompatible normal mouse strain combinations, liver transplant tolerance is achieved without the need for host immunosuppression (1). In contrast, skin allografts in the same combinations are rejected acutely. The mechanisms underlying "spontaneous" liver acceptance are poorly understood (2, 3). Liver acceptance occurs despite early intragraft mononuclear leukocyte infiltration (1) , that appears identical histologically to that observed in organ rejection, and that may reflect the "active" nature of liver-induced tolerance. Indeed, it has been suggested that, because liver tolerance in rats can be inhibited by steroid administration for the first 2 days after transplant, immune activation is key to the induction of donor-specific unresponsiveness (6) . With the acceptance of liver allografts, the recipients become permanently tolerant to donor-type challenge grafts, such as those of heart and even skin, indicating the robust nature of the tolerance (1, 38, 39) . The process of tolerance induction can be prevented, however, by presensitization of the liver recipient to donor alloantigens, usually by skin grafting 2 weeks or more before organ transplantation (40) . With recipient presensitization, the liver is rejected acutely (within 4-5 days). Mouse liver allograft rejection also results from recipient treatment with recombinant mouse interleukin (lL)-2 (14) or IL-12 (4]),
In recipients of normal liver allografts, graft NPCs isolated during the first week after transplant exhibit strong, donorspecific CTL responses. This "paradoxical" CTL activity, detected using donor MHC-positive cells as targets, correlates well with the extent of the histologic infiltrate that peak; between days 4 and 7, then diminishes rapidly and progre sively to normal levels. Despite these findings, there is litt . evidence of either bile duct or hepatocyte injury in the norm,,] mouse liver allograft recipient. Taken together, these observations suggest that, although donor-specific immunity is induced initially, it wanes rapidly as a result of the elimination of donor-specific CTL within the graft. Apoptosis of graft-infiltrating cells (14) by mechanisms yet to be elucidated may play a key role in the process. It is conceivable that donor liver-derived NPCs or DCs (that may express Fas ligand [CD95L]) (42) could playa key role in the apoptosis of recipient activated T cells. The capacity of exogenous IL-2 to induce normal liver allograft rejection (41) may reflect protection of graft-infiltrating T cells from apoptosis (14) . By contrast, the results of the present study show that dramatic increases in donor leukocytes, in particular functional DC leads to augmented early antidonor CTL activity of liv. graft-infiltrating cells, hepatocellular destruction, and all(,-graft rejection. The observed increase in apoptosis of parenchymal cells is most likely due, predominantly, if not exclusively, to the cytotoxic activity of host immune effector cells. The stimulus provided to unmodified hosts by substantially increased numbers of immunostimulatory donor DCs and probably other APCs is sufficient to overcome other mechanisms that generally contribute to the success of liver allografts.
As reported previously (29) , treatment with FL for 10 days resulted in a dramatic accumulation of myelomonocytic cells within the liver, both in portal areas (where DCs are normally found; 8), and throughout the parenchyma. Augmentation of the number of myeloid lineage cells far exceed( I that of lymphocytes, although these too were increased si. nificantly in absolute numbers. The largest increase (> 10U-fold) was observed in the absolute number of cells bearing the DC-restricted cell surface antigenic markers DEC-205 or CDllc. The most striking evidence of the large increase in DCs within FL-treated mouse livers was, however, the huge increase in the absolute number ofCDllc+ cells that could be recovered after overnight culture of liver NPCs. Evidence that these cultured cells had rapidly undergone functional maturation was provided by the high levels of surface MHC class II, CD40, CDSO, and CDS6, and their potent allostimulatory capacity. These findings are consistent with recent reports that FL may preferentially mobilize or enhance the development of myeloid (28, 29) or myelomonocytic linea! ' cells (43) , and also enhance DC accumulation in mouse t sues (28) . This in tum, may be associated with increasi i levels of secreted IL-12 and/or other cytokines/growth factor:; that promote graft immunogenicity, and possibly, DC proliferation. DC-derived IL-12 could augment CD4 + Thl cell responses that have been linked previously to murine liver allograft rejection (4, 41) . Although not examined in the present study, it is conceivable that a component of the multilineage NPC accumulation within the liver is derived from local lineage-committed progenitor cell proliferation and maturation (30) . This could also be achieved through June 27, 1998 QIANET AL.
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proliferation of stem cells in the liver (44, 45) induced or enhanced by FL administration.
As shown previously, both in mouse and rat models, systemic effects of normal liver transplantation include the capacity of liver leukocytes (including progenitor and stem cells) (1, 5, 46, 47) , to migrate extensively to recipient lymphoid and nonlymphoid tissues, where they may persist indefinitely. These donor-derived cells may provide not only a continuing source of allostimulation, but may also have the capacity to modulate the survival and function of alloactivated T cells within the recipient lymphoid system (10, 48, 49) . Key molecules that may be expressed by donor-derived Des, including costimulatory molecules (22, 42) , inducible nitric oxide synthase (37) , and Fas ligand (42) could play important regulatory roles in these cell interactions. Recently, emphasis has been placed on multilineage donor hematolymphopoietic cell chimerism as the basis for organ allograft acceptance (9, 48, 49) . Although tolerance and chimerism are spontaneous in the mouse liver transplant model (1, 2) , they require an umbrella of immunosuppression in most models (including human organ transplantation) to prevent one of the interacting donor and recipient immune populations from overwhelming the other (50) . With an uncontrolled imbalance, the result is rejection or graft-versushost disease (51) . It has been emphasized as a therapeutic principle, that attempts to augment donor chimerism clinically with either adjunct donor leukocytes (i.e., bone marrow [BM] cells) or by administration of hematolymphopoietic growth factors, is predictably unsafe, unless it is done under immune suppression that affects both cell populations equally (49) . The present study reinforces this warning by demonstrating that augmentation with FL treatment of potentially potent immunostimulatory cells in a liver allograft before its transplantation can lead to an enhanced rejection reaction and graft loss in an otherwise spontaneously tolerant host. In contrast, FL treatment of the mouse allogeneic BM cell recipient, rather than the donor under coverage of immunosuppression (tacrolimus) from the time of BM infusion, results in a striking enhancement of chimerism (52) .
Studies such as those reported herein provide compelling in vitro immunologic evidence that the timing and circumstances of FL administration may determine the balance between transplant tolerance and immunity. Precisely how this balance is accomplished by the De and other lineages, or influenced by growth factors or immunosuppression, remains speculative. Further studies of FL and other hematopoietic growth factors in the mouse liver transplantation model may help elucidate the role of donor-recipient hematopoietic cell interactions in determining graft acceptance. Our findings also support the prediction that under the appropriate circumstances, FL-mediated expansion offunctional Des in the liver may provide effective strategies to increase immunologic resistance to liver cancer and infectious diseases, such as viral hepatitis. It has been obvious since the studies of Knight et a1. (53) that "blind" attempts to engineer such immunity could lead inadvertently to tolerance, and vice versa.
